PaxVax reports positive results from cholera vaccine trial
The efficacy rate of the PXVX0200 vaccine 90 days after its administration was 79.5 percent in study participants. Four of the 33 participants who received the vaccine experienced symptoms, while 39 of 66 who received a placebo reported moderate to severe diarrhea.
"The 90-day challenge results are very encouraging and provide important new data that further support the efficacy of PXVX0200 in protecting people exposed to cholera," Beth Kirkpatrick, a study investigator and professor of medicine and infectious disease at the University of Vermont, said. "If approved, PXVX0200 has the potential to provide an effective new single-dose option for people living in and travelling to areas where cholera is endemic."
The randomized, double-blind trials were conducted at the Center for Vaccine Development at the University of Maryland School of Medicine, the University of Vermont Vaccine Testing Center and the Cincinnati Children's Hospital Medical Center.
PaxVax is currently conducting a broader Phase III clinical study of the vaccine at sites in Australia, Canada and the U.S. Approximately 3,000 participants are enrolled in the study.
There are no cholera vaccines available in the U.S. for those traveling to areas such as Haiti or Central Africa. A two-dose vaccine is available in Europe and elsewhere.